Donald Marks, MD
Neurology · Plymouth, MANPI 1982680740
Payments from drug & device makers
Across 398 payments — averaging $19,624 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3.8M
- Eisai Inc.$2M
- Biogen$1.8M
- E.r. Squibb & Sons, L.L.C.$222K
- Alnylam Pharmaceuticals Inc.$1K
- Genentech USA, Inc.$162
- plus $287 from 11 others
Across 11 payments — averaging $3778.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$27K
- Eli Lilly$9K
- E.r. Squibb & Sons, L.L.C.$6K
What the payments were for
- Consulting fees$12,81324%
- Speaking & faculty fees$26,37550%
- Travel & lodging$10,47420%
- Food & beverage$2,8655%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 44 | $3,828,413 |
| Eisai Inc. | 296 | $1,997,164 |
| Biogen | 26 | $1,761,153 |
| E.r. Squibb & Sons, L.L.C. | 7 | $221,809 |
| Alnylam Pharmaceuticals Inc. | 9 | $1,259 |
| Genentech USA, Inc. | 4 | $162 |
| Lilly USA, LLC | 1 | $69 |
| Novartis | 2 | $47 |
| Life Molecular Imaging Ltd | 1 | $28 |
| Adamas Pharmaceuticals, Inc. | 1 | $23 |
| Sanofi | 1 | $21 |
| Abbott | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Neuronetics, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,810,248 in reported general payments places this provider in the 95th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Galantamine ErGalantamine Hbr | 50 | $3,337 |
| Memantine Hcl | 86 | $2,790 |
| Rivastigmine | 16 | $2,401 |
| Donepezil Hcl | 210 | $2,004 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 53 | $1,703 |
| AmantadineAmantadine Hcl | 13 | $1,260 |
| Levetiracetam | 51 | $1,231 |
| Mirtazapine | 14 | $794 |
| Quetiapine Fumarate | 34 | $430 |
| Sertraline Hcl | 56 | $343 |
| Trazodone Hcl | 41 | $251 |
| Escitalopram Oxalate | 18 | $165 |
Paid to pharmacies, not to this prescriber.
Other neurology in Plymouth
- Stephanie RutrickBoston$31.4M
- Scott PlotkinBoston$26.3M
- Patrick WenBoston$18.2M
- James BerryBoston$8.9M
- Isabel Arrillaga-RomanyBoston$8.2M
- Mahmut GurolBoston$7.4M
- Gad MarshallBoston$6M
- Shawn MurphyBoston$5.9M
- Suma BabuBoston$5.8M
- Luis Gonzalez CastroBoston$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.